AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca PLC closed 23.78% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

Another notable valuation metric for AZN is its P/B ratio of 5.44. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

On Friday, AstraZeneca Plc AZN reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of ...

(RTTNews) - AstraZeneca Plc.'s (AZN.L, AZN) triple-combination inhaler, Breztri Aerosphere, has shown positive results in late-stage clinical trials for patients with uncontrolled asthma. The ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £151.31. The company’s shares opened today ...

AZN market cap is currently $241.1B and has a P/E ratio of 38.15. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions.

If an investor was to purchase shares of AZN stock at the current price level of $68.53/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...